Abstract

Introduction: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, accounting for 1-3% of all gastrointestinal malignancies. The most common site of origin within the gastrointestinal tract is the stomach, followed by the small bowel. The clinical presentations of GISTs are highly variable according to the site of origin and the anatomic size, and the majority of tumors is not pathognomonic. GISTs are indeed often diagnosed incidentally during investigations performed for other reasons. The preoperative radiological diagnosis of GISTs is complicated by their varied macroscopic morphology. Moreover, the precision of preoperative histopathological diagnostics is reduced by the submucosal localization of the lesion. Surgical resections is the ‘gold standard’ therapeutic choice of primary GISTs. Recently, a targeted therapy with inhibitors of tyrosine kinase receptors (imatinib) has been introduced for the management of advanced and metastatic tumors.

Aim of the study: The present study was designed in order to assess the survival of GIST-diagnosed patients after surgical resection, to identify factors that could have a prognostic impact and finally evaluate the role of Imatinibmesylate as therapeutic option in this group of individuals.

Materials and methods: We retrospectively collected 88 consecutive patients who were diagnosed with GIST and surgically resected in our center (Department of General Surgery, ‘San Matteo’ Hospital, Pavia) in the last 15 years (January 2000-December 2014). General and clinical data were reviewed from patients’ medical reports: symptoms at presentation, clinical course, histopathological features, type of surgery, post-surgical complications and disease-free survival.

Results: 45 (51.13%) out of 88 patients were male, 43 (48.86%) were female. The median age of our study population was 55 years. Most tumors originated in the stomach (63.63%, 56), 22.72% (20) were isolated from the small intestine, duodenum (3.4%, 3), colon (3.4%, 3), esophagus (2.27%, 1) or elsewhere. Tumor size was less than 2.0 cm in 2 patients, between 2.0 and 5.0 cm in 36.63% (34) of patients, between 5.0 and 10.0 cm in 25% (22) of patients, and greater than 10.0 cm in 13.63% (12). Twenty-one patients presented with gastrointestinal bleeding (23.86%), 17 patients with intestinal obstruction (19.3%), 8 with intraperitoneal haemorrhage (9.09%) and 4 with perforation and peritonitis (4.5%). Thirty-eight patients (43.01%) were asymptomatic and diagnosed incidentally during investigations performed for other reasons. Complete macroscopic resection (Wedge+Partial organ resection) was performed in 74 patients (84.1%), total organ resection and peritoneal biopsy were chosen for 9 patients (10.22%), while 5 patients (5.685) received “en-bloc” resection. Forty-six patients (52.27%) out of 88 patients underwent postoperative (adjuvant) treatment with Imatinib and only one isolated patient received a combination of Imatinib and Sunitinib. 23 (26.14%) patients did not need any adjuvant therapy but only a close follow up with Computed Tomography (CT) and blood tests monitoring every 3/6 months. We were not able to collect data from 18 (20.45%) patients who did not presented at the follow-up visits.

Conclusion: GISTs constitute an interesting chapter of oncological pathologies. Surgery is still the gold standard treatment in localized primary GIST. Still a little number of cases with low risk disease can be treated with radical surgery. The prognosis is strictly related to the size and completeness of the surgical resection. Large size, high mitotic rate, high risk group, and adjacent organ involvement all contribute to bad outcome of GISTs. Imatinib therapy significantly improves survival of patients with intermediate-high risk or advanced staging.

Keywords: Gastrointestinal Stromal Tumors; Imatinib; Surgery

Introduction

Gastrointestinal Stromal Tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal (GI) tract [1]. Currently, they are recognized and classified as distinct entities from other neoplasms of the connective tissue, with specific clinical and histopathological features. Although the majority of them is small in size, their diameter can vary from 1 to 20 cm. Metastasis occur mostly in the abdominal cavity and liver. The nodal involvement is less frequent: either pulmonary or extra-abdominal lymph-nodes metastasis have an extremely low incidence in comparison to what happens for epithelial neoplasms [1-3]. The reported annual incidence is about 10-20 cases to 1 million of individuals [2]. These tumors occur at any time during life, but the median age at diagnosis has been reported to be 55-60 years [3], affecting males and females at the same rate. Although they most commonly occur in the stomach (50-70% of cases), followed by...
the small intestine (20-30% of cases) and duodenum 5% [4,5]. GISTs are found throughout the GI tract. Locations such as the esophagus, the colon and the rectum account for less than 10% of all cases [4,5]. Uncommonly, they can also arise within the greater omentum, appendix and gallbladder. The interstitial cells of Cajal, pluripotent intestinal pacemaker cells, were identified as the origin of GISTs [6].

A gain-of-function sporadic mutation within the tyrosine kinase receptor’s gene plays a fundamental role in their pathogenesis, being responsible for the deregulation of processes involved in the cell cycle control, thus leading to cell hyper-proliferation [7]. Tyrosine kinase receptor (C-KIT) is a transmembrane receptor that is activated by the binding of KIT protein, a C-KIT proto-oncogene product. Up to 80% of GISTs have KIT protein mutations, while 8% have mutations in the Platelet derived growth factor receptor a (PDGFRa), a-polypeptide gene encoding a C-KIT homologous type III receptor tyrosine kinase protein [8]. The essential ligand-independent activation of the mutated KIT protein results into imbalance between cell survival and proliferation, overcoming the natural process of programmed cell death [9]. GISTs specific immunohistochemical markers are CD117 (95% positivity), CD34 (70-80% positivity), Smooth Muscle Actin (20-30% positivity), and Desmin (<5% positivity) [10].

GISTs are frequently asymptomatic until advanced stages. Small tumors are usually incidental findings during surgical, endoscopic or radiological investigations for other reasons. There are no pathognomonic symptoms and for this reason a high-level of suspicion for GISTs should be kept during the diagnostic work-up of patients presenting with GI bleeding, intestinal obstruction, intraperitoneal hemorrhage or peritonitis. The most frequent signs are anemia, weight loss and bleeding. Symptoms are mainly abdominal pain and mass-related effects. Patients may complicate with acute abdomen, obstruction, perforation and eventually peritonitis. Other presentations include nausea, vomiting, and abdominal distension [3].

GISTs present a varied of morphological appearances and this feature may further complicate their pre-operative diagnosis through imaging. Their histopathological determination may result cumbersome due to possible submucosal localizations, reducing the accuracy and reliability of biopptic procedures. Ultrasound endoscopy is the first step of the diagnostic workup, followed by cross-sectional imaging techniques such as Computed Tomography (CT) and/or magnetic resonance imaging (MRI). There are several criteria for risk stratification, Fletcher’s criteria is the first attempt in assessing the malignant potential of GISTs. The parameters determining risk stratification are mainly two: tumor size and mitotic activity. According Miettinen and Lasota the criteria for risk stratification are mainly three: tumor size, mitotic count and tumor location [11-13].

Surgical resection remains the gold-standard procedure for an efficacious treatment of very-low and low risk disease, while the additional use of oral inhibitors like Imatinib Mesylate (trade name: Gleevec, Glivec) is considered in patients with unresectable or metastatic disease [14]. Conventional chemotherapy and radiotherapy are usually ineffective [15,16]. Imatinib Mesylate belongs to a class of chemotherapeutic agents that act as specific inhibitors of a number of tyrosine kinase enzymes, linked to the C-KIT receptor. More specifically, it blocks the kinase activity of the mutated polypeptide codified by the C-KIT proto-oncogene (CD117) involved in tumor growth. It also has inhibitory activity on mutated PDGF-R (platelet derived growth factor receptor), a well known factor regulating cell proliferation, differentiation, growth and development. Initially introduced as treatment for chronic myeloid leukemia and acute lymphoblastic leukemia, Imatinib was later approved in 2001 as therapeutic option in metastatic GISTs [17,18]. The starting recommended dose is 400 mg per day, to be increased up to 800 mg in case of resistance or disease progression. The best achievable response is obtained within the first 6-12 months. Therapeutic benefits usually decline after a year of treatment, at this time resistance indeed is as high as 15-20%. Surgery should be considered if any improvement can be observed at CT scan after 6 months of treatment with Imatinib. The ideal surgical moment is after the maximum response and before the onset of resistance. Another chemotherapeutic option is Sunitinib (Sutent), a recently validated drug, designed to work as tyrosine kinase inhibitor applied for the treatment of Imatinib-resistant or-intolerant GISTs. In addition to the inhibition of tyrosine kinase activity, Sunitinib action extends also to the hindrance of the angiogenic activity proper of VEGF (vascular endothelial growth factor) [19-21].

**Aim of the study**

The purpose of this retrospective study was to assess the survival after surgical resection and prognostic factors of patients who received a diagnosis of GIST. We also retrospectively evaluated the role of Imatinib Mesylate in affecting the outcome of a group of patients that after surgery needed such a therapy. This article reviews risk stratification in resectable GISTs and illustrates how recent findings may not only improve risk assessment but also indentify who are potentially most likely to benefit from adjuvant therapy.

**Material and Methods**

Eighty-eight patients with a confirmed diagnosis of GIST who were admitted to the Surgery Department at the ‘San Matteo’ Hospital of Pavia between January 2000 and December 2014 were enrolled. Each patient agreed to sign the informed consent. The study received official institutional and ethical approval from the participating institutions. We retrospectively reviewed the medical records and disease-free survival of 88 patients who underwent surgical removal of GISTs. Data on patients’ gender, age, clinical presentations, tumor characteristics, histo-pathological features, clinical course, pathological findings, radiological investigations, type of surgical procedure, classification of risk according to Fletcher and Miettinen, treatment with Imatinib Mesylate, number of postoperative recurrences and overall survival and disease-free survival, intra- and post-operative complications were collected and summarized into three table.

Their clinical presentation is aspecific and highly variable according to their site and size. There are no precise criteria for pre-operative diagnosis because GISTs are frequently asymptomatic until advanced stages, that’s why only the symptoms and imaging techniques do not allow us to get a diagnosis. According to Cavaliere et al., [22], the difficulty in having a pre-operative diagnosis comes mainly from the aspecificity of the symptoms and the possibility to have a definitive diagnosis only after performing the pathological, histological and immunological analysis of the excised tumour. Morphological and immunohistochemical examinations of C-KIT expression allow the correct identification of GIST enabling the differential diagnosis with other mesenchymal, neural and neuroendocrine neoplasms occurring in the abdomen. A diameter greater than 2 cm is usually a positive indication for surgical resection, whilst lesion smaller than this threshold are closely monitored for metastasis [23,24]. The prognosis is mainly related to size and completeness of surgical resection but the large size, a high mitotic rate, classification into high-risk group, and adjacent organ involvement are all contributors to a dismal outcome of GISTs. Patients with a GIST’s size less than 5 cm had a significantly longer survival than patients with bigger tumors. Katharine et al., [25]
found that tumor size had a significant impact on overall survival. Patient with advanced-stage GISTs usually face severe morbidity and short life-expectancy. It was estimated that 47 (53.41%) out of 88 patients underwent postoperative treatment with Imatinib and only 1 case received a combination of Imatinib and Sunitinib. Twenty-two (25%) patients did not need adjuvant chemotherapeutic support but were recommended for a close follow-up with Computed Tomography (CT) and blood analysis every 3–6 months. All the surgical specimens underwent histopathological examination and immuno-histochemical staining for detection of C-KIT (CD117). Early and late post-operative complications, local and distant recurrence and mortality rates were recorded during the follow-up period.

### Results

All the patients enrolled in this study had a definitive diagnosis of GIST assessed post-operatively by an anatopathologist through morphological, histological and immunohistochemical analysis. In our study, all the patients underwent surgery. The characteristics of the 88 patients are summarized in Table 1. The median age of our study population was 55 years, 51.13% (45) of patients were male. Twenty-one (23.86%) patients presented with gastrointestinal bleeding, 17 (19.3%) with intestinal obstruction, 8 (9.09%) with intraperitoneal hemorrhage and 4 (4.5%) with rupture and peritonitis. Thirty-eight (43.01%) patients were asymptomatic and were diagnosed incidentally during investigations performed for other conditions. Patients presenting hematemesis and/or melena (35, 39.77%) were investigated through upper GI endoscopy followed by biopsic sampling, patients reporting fresh bleeding from the rectum (4, 4.55%) received colonoscopy. Computed tomography (CT) scan of the abdomen and pelvis was performed in all the cases. Most tumors originated in the stomach (63.63%, 56), 20 in the small bowel (22.72%), 3 of the abdomen and one single case (1.13%) respectively in the rectum, pancreas, liver and spleen. The average size of tumors was 9.1 cm (range 0.5–19 cm). Tumor size was less than 2.0 cm in 22.72% (20) of patients, between 2.0 and 5.0 cm in 38.63% (34) of patients, between 5.0 and 10.0 cm in 25% (22) of patients, and greater than 10.0 cm in 13.63% (12). Mitotic rates were also determined: most tumors (53.40%, 47) had a low mitotic rate (<5/50 HPFs), 35.22% (31) in the duodenum (3.4%), 3 in the colon (3.4%), 2 in the esophagus (2.27%), and only 1 single case (1.13%) respectively in the rectum, pancreas, liver and spleen. Immunohistochemistry showed that 31 (35.22%) tumors were positive only for CD117, 6 (6.81%) positive only for CD34, and 51 (57.95%) positive for both CD117 and CD34. The 88 patients were classified as follows according to the cells morphology type founded on histologic examination of the surgical specimen: Spindle cell (48 patients (54.54%), epithelioid 23 (26.13%), mixed 17 (19.31%), low risk 7 (7.95%), intermediate 30 (34.09%), high risk 36 (40.95%). Risk according Fletcher findings allowed Fletcher to combine these criteria in a new scale “risk of aggressive behaviour classification of GIST”, considering only tumor size and mitotic count [26,27]. Our 88 patients were classified according to Fletcher risk classes as follows: 7 (7.95%) of patients were classified as

### Table 1: Clinico-pathological features.

| Patients, n (%) | Age | < 55 years | 35 (39.77%) | > 55 years | 53 (60.22%) |
|----------------|-----|------------|-------------|------------|-------------|
| Sex | Male | 45 (51.13%) | Female | 43 (48.86%) |
| Symptom | Asymptomatic | 38 (43.1%) | Gastrintestinal bleeding | 21 (23.86%) | Intestinal obstruction | 17 (19.3%) | Intraperitoneal hemorrhage | 8 (9.09%) | Rupture and peritonitis | 4 (4.5%) |
| Location | Gastric | 56 (63.63%) | Ileum | 20 (22.72%) | Duodenum | 3 (3.4%) | Colon | 3 (3.4%) | Esophagus | 2 (2.27%) | Rectal | (1.13%) | Liver | (1.13%) | Pancreatic | (1.13%) |
| Tumor size | < 2 cm | 20 (22.72%) | > 2 and < 5 cm | 34 (38.63%) | > 5 and < 10 cm | 22 (25%) | > 10 cm | 12 (13.63%) |
| Mitotic count | < 5/50 HPF | 47 (53.40%) | > 5 and < 10/50 HPF | 31 (35.22%) | > 10/50 HPF | 10 (11.36%) |
| Immunohistochemistry | KIT exon CD117 | 31 (35.22%) | KIT exon CD34 | 6 (6.81%) | Wild-type | 51 (57.95%) |
| Morphological Type | Spindle cell | 48 (54.54%) | Epithelioid cell | 23 (26.13%) | Mixed cell | 17 (19.31%) | Very low | 7 (7.95%) | Low | 30 (34.09%) | Intermediate | 15 (17.04%) | High | 36 (40.95%) |
| Risk according Fletcher | No risk | 13 (14.7%) | Low | 47 (53.40%) | Intermediate | 18 (20.45%) | High | 10 (11.36%) |

### Table 1: Clinico-pathological features.

| Partial | Total |
|---------|-------|
| Gastric | 22 (53.65%) |
| Ileum | 13 (31.70%) |
| Colon | 3 (7.31%) |
| Rectal | 1 (2.43%) |
| Duodenum | 1 (2.43%) |
| Esophagus | 1 (2.43%) |
| 9 (10.22%) |
| 1 Gastrectomy and right liver lobectomy | 1 (11.11%) |
| 1 Gastric and splenectomy | 1 (11.11%) |
| 1 Gastric and transverse colon resection | 1 (11.11%) |
| 1 Gastric, ileum resection and liver biopsy | 1 (11.11%) |

HPF = High Power Fields.
very-low risk group, 30 (34.09%) low risk, 15 (17.04%) intermediate risk and 36 (40.90%) high-risk. Miettinen criteria for the risk classification take into account mitotic count, size and tumor location [28,29]. Our 88 patients were classified according to Miettinen risk classes as follows: no risk 13 patients (14.70%), low 47 (53.40%), intermediate 18 (20.45%), high 10 (11.36%).

Surgical management entailed different technical options: 33 (37.5%) wedge resection (21 of which were located in the stomach, 7 in the ileum, 2 in the duodenum, 1 in the liver, 1 in the pancreas, and 1 in the esophagus); 41 (46.59%) partial organ resections (22 gastric resection, 13 resections of the small bowel, 3 colon resection, 1 colorectal resection, 1 duodenal resection, 1 esophagogastric resection); 8 (9.09%) total gastrectomy and 1 (1.14%) spleenectomy; 5 (5.68%) resection "en bloc" (gastrectomy+right liver resection, gastrectomy+left liver resection, 1 gastric and ileum resection, 1 gastrectomy and splenectomy, 1 gastric and transvers colon resection) (Table 1 and Figure 1). Of these latter, 4 had tumor rupture and peritonitis. The organs most targeted by metastasis were the liver (61.53%), ileum (15.38%), omentum/peritoneum (15.38%), while lymph nodes and extra-abdominal sites were rarely affected. Only one patient who underwent "en-bloc" gastric and transverse colon resection didn't experience tumor rupture and peritonitis. The first patient, who initially underwent total gastrectomy and left liver lobectomy, had 4 further interventions for disease relapse. He was 39 years old at the time of diagnosis. After the first surgery, the treatment with Imatinib was initiated at a starting dose of 400 mg, subsequently increased to 800mg after 12 months of therapy. At the end of the fifth year, during which 4 additional surgical attempts were tried, a complementary dose of 37.5 mg of Sunitinib was added to the chemotherapeutic scheme. He died after five surgical operations and 86 months of follow-up and partial response to Imatinib and Sunitinib. In our series we have not found any other patient who needed treatment with sunitinib as second-line.

In the second Table we classified our patients according to their clinical - pathological characteristics in 4 groups: Male >45 years and <45 years old, Female >45 years and <45 years old (Table 2).

Based on the clinical data, we found out that the group of male >55 years had the worst prognosis followed by female >55 years. They had the largest number of patients 28 (31.8%), with more cases of gastrointestinal bleeding 9 (10.22%), whose tumors are located mainly in the stomach 18 (20.45%) and ileum 6 (6.81%) but also in some cases the duodenum 1 (1.13%) and esophagus 1 (1.13%), which dimensions are greater 8 (9.09%) >5 cm <10 cm and 5 (5.85%) >10 cm, with high mitotic index 11 (12.5%) 6-10/50 HPF and 7 (7.95%) >10/50 HPF. This group has the highest number of cases with mutation of exon CD117, 14 (15.9%) and CD34, 5 (5.86%). The prevalent cell morphological type was as follow: spindle cell 16 (18.18%), epithelioid 7 (7.95%), mixed 5 (5.68%). They had the highest grade of malignancy: moderate 9 (10.22%), high 5 (5.68%) and the greater number of recurrencies: 6 liver (46.15%), 1 omentum (7.69%) and 1 spleen (7.69%) after 6 months of surgical intervention and Imatinib Mesylate therapy into a total of 13 patients with gastrointestinal bleeding vs No GI bleeding (61.53%), ileum (15.38%), omentum/peritoneum (15.38%), while lymph nodes and extra-abdominal sites were rarely affected. Only one patient who underwent "en-bloc" gastric and transverse colon resection didn't experience tumor rupture and peritonitis. The first patient, who initially underwent total gastrectomy and left liver lobectomy, had 4 further interventions for disease relapse. He was 39 years old at the time of diagnosis. After the first surgery, the treatment with Imatinib was initiated at a starting dose of 400 mg, subsequently increased to 800mg after 12 months of therapy. At the end of the fifth year, during which 4 additional surgical attempts were tried, a complementary dose of 37.5 mg of Sunitinib was added to the chemotherapeutic scheme. He died after five surgical operations and 86 months of follow-up and partial response to Imatinib and Sunitinib. In our series we have not found any other patient who needed treatment with sunitinib as second-line.

Based on the clinical data, we found out that the group of male >55 years had the worst prognosis followed by female >55 years. They had the largest number of patients 28 (31.8%), with more cases of gastrointestinal bleeding 9 (10.22%), whose tumors are located mainly in the stomach 18 (20.45%) and ileum 6 (6.81%) but also in some cases the duodenum 1 (1.13%) and esophagus 1 (1.13%), which dimensions are greater 8 (9.09%) >5 cm <10 cm and 5 (5.85%) >10 cm, with high mitotic index 11 (12.5%) 6-10/50 HPF and 7 (7.95%) >10/50 HPF. This group has the highest number of cases with mutation of exon CD117, 14 (15.9%) and CD34, 5 (5.86%). The prevalent cell morphological type was as follow: spindle cell 16 (18.18%), epithelioid 7 (7.95%), mixed 5 (5.68%). They had the highest grade of malignancy: moderate 9 (10.22%), high 5 (5.68%) and the greater number of recurrencies: 6 liver (46.15%), 1 omentum (7.69%) and 1 spleen (7.69%) after 6 months of surgical resection and Imatinib Mesylate therapy into a total of 13 patients with recurrences of 47 patients Imatinib Mesylate treated (Tables 2 and 3).
The had the highest number of patients treated with postoperatively Imatinib therapy 18 (38.29%) and the worst 3-year overall survival of 22%. They had the highest number of patients treated with postoperatively Imatinib treatment; 9 (19.14%) patients with intermediate/high risk tumors had recurrences after resection and presented a 3-year disease-free survival of 52%; they are alive and still under treatment with Imatinib. Four (8.51%) patients with high risk tumors had 3-years disease-free survival of 22%, they relapsed after surgery despite Imatinib therapy and at the end died from advanced-GIST. Eight (17.02%) patients with very-low, low, intermediate and high risk tumors, with 3-year disease-free survival of 76%, operated and treated with Imatinib for GIST died from other diseases.

Conclusions

GISTs constitute an interesting chapter of oncological pathologies, because of their relative rarity, biological aggressiveness and diagnostic/therapeutic problems that frequently arise. The main concerns regarding this class of tumors are: the exploitation of immunohistochemical tools such as the use of KIT (CD117) markers for diagnostic purposes, and secondly the development of monoclonal therapeutic options targeting CD117 in order to provide a new valuable tool against metastatic and recurrent GISTs [30-37].

We recommend that all patients with a GIST should be carefully and regularly followed-up for an indefinite period. Still nowadays surgery remains the unconditioned choice for very-low and low risk GIST but in cases of intermediate, high-risk tumors, advanced or relapsed disease, new optimistic strategies are now represented by targeted therapies against c-kit. The clinical impact of the c-kit receptor targeting drugs (Imatinib–Gleevec) in GISTs has been so far confirmed in phase I and II trials [38-40], and it will likely improve the outcome of CD117-positive GISTs and of those cases not suited for radical surgery. In our study, we have seen that almost all patients treated with Imatinib after surgery had a good clinical response, only few patients with very advanced-GIST tumors at diagnosis had a partial response to the treatment and the results of secondary surgery were anyway generally poor. In summary, Gleevec is the only effective treatment for advanced-GIST. Eight (17.02%) patients with very-low, low, intermediate and high risk tumors, with 3-year disease-free survival of 76%, operated and treated with Imatinib for GIST died from other diseases.

Table 2: Clinicopathologic characteristics of patients with primary GISTs among 4 groups (n=88).

| Grade of malignancy | Liver | Ileum | Omentum | Spleen | Postoperative IM treated (total = 47 patients) | Overall survival (3 years %) | Disease free survival (3 years %) |
|---------------------|-------|-------|---------|--------|-----------------------------------------------|-----------------------------|----------------------------------|
| Low                 | 15    | 16    | 1       | 7      | 9 (38.29%)                                    | 45%                         | 22%                             |
| Moderate            | 10    | 7     | 1       | 3      | 9 (19.14%)                                    | 82%                         | 76%                             |
| High                | 5     | 3     | 1       | 1      | 5 (7.69%)                                     | 52%                         | 34%                             |
|                     |       |       |         |        |                                               | (Follow-up 1-126 months)    | (Follow-up 1-112 months)        |

Table 3: Patients treated with IM therapy in the follow-up.

| Patients (total 47) | Nr. Patients (%) | Follow-up (months) | 3-year DFS (Disease-free survival) (%) | Fletcher’s criteria |
|---------------------|------------------|-------------------|---------------------------------------|---------------------|
| Alive (- DFR. - IM) | 26 (55.31%)      | Between 1 and 78 months | 94% | VLR 8 16 2 |
| Alive (+DFR. + IM)  | 9 (19.14%)       | Between 1 and 129 months | 52% | LR 4 5 |
| Died from other diseases (D/R. +/- IM) | 8 (17.02%) | Between 1 and 61 months | 76% | IR 2 3 3 |
| Died from GIST (+DFR.+IM) | 4 (8.51%) | Between 1 and 176 months | 22% | HR 4 |

GISTs: Gastrointestinal Stromal Tumors; GI: Gastrointestinal; HPF: High Power Fields; IM: Imatinib Mesylate. *Others including omentum. mesentery of small intestine and large intestine. retroperitoneal. pancreatic. rectal. liver and spleen. SR: Surgical Resection.
References

1. Shafraz A, Mohammadianpanah M, Nasrolahi H, Mokhtari M, Mousavi SA (2014) Lymph Node Metastasis in Gastrointestinal Stromal Tumor (GIST): To Report a Case. Iran J Cancer Prev 7: 171-174.

2. Agarwal R, Robson M (2009) Inherited predisposition to gastrointestinal stromal tumors. Hum Pathol 39: 1411-1419.

3. Wang M, Xu J, Zhang Y, Tu L, Qiu WQ, et al. (2014) Gastrointestinal stromal tumor: a size-matched comparison. Ann Surg Oncol 21: 265-274.

4. Niedźwiecki S, Piekarski J, Jeziorski A (2014) The clinical and histopathological factors in patients operated on for gastric GIST tumors with unclear diagnosis. Adv Clin Exp Med 23: 567-573.

5. Joensuu H (2008) Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 39: 1411-1419.

6. Wang M, Xu J, Zhang Y, Tu L, Qiu WQ, et al. (2014) Gastrointestinal stromal tumor: 15-years’ experience in a single center. BMC Surg 14: 93.

7. Al-Thani H, El-Menayar A, Rasul IK, Al-Sulaiti M, El-Mabrok J, et al. (2014) Clinical presentation, management and outcomes of gastrointestinal stromal tumors. Int J Surg 12: 1127-1133.

8. Ferrarese F, Cecere V (2006) Gastro-intestinal stromal tumors (GISTs): prognostic and therapeutic features. G Chir 27: 205-208.

9. Joensuu H (2006) Gastrointestinal stromal tumor (GIST). Ann Oncol 17 Suppl 10: x265-266.

10. Cavallo A, Lauretta A, Cavallaro M, Pennisi S, Cavallaro V (2006) Surgery on gastrointestinal stromal tumor CD117+ (GIST): personal experience. Ann Ital Chir 77: 137-141.

11. Gheza F, Pulcini G, Cervi E, Ferrari AB, De Cesare V, et al. (2010) Surgical treatment of non-metastatic gastric GIST: two cases and review of the literature. G Chir 31: 33-37.

12. Gold JS, Dematteo RP (2006) Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg 244: 176-184.

13. Tran T, Davila JA, El-Serag HB (2005) Gastrointestinal stromal tumors: epidemiology, clinical picture, diagnosis, prognosis and treatment. Pol Arch Med Wewn 118: 216-221.

14. Yao KA, Talamonti MS, Langella RL, Schindler NM, Rao S, et al. (2000) Primary gastrointestinal sarcomas: analysis of prognostic factors and results of surgical management. Surgery 128: 604-612.

15. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, et al. (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet 358: 1421-1423.

16. Rutkowski P, Wozniak A, Debiec-Rychter M, KAKOL M, Dziewirski W, et al. (2011) Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection. Cancer 117: 4916-4924.

17. Kong SH, Yang HK (2013) Surgical treatment of gastric gastrointestinal stromal tumor. J Gastric Cancer 13: 3-18.

18. Joensuu H, Vehtari A, Rikimäki J, Nishida T, Steigen SE, et al. (2012) Risk of recurrence of gastrointestinal stromal tumor after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 13: 265-274.

19. Boni L, Benevento A, Dionigi G, Rovera F, Dionigi R (2005) Surgical resection for gastrointestinal stromal tumors (GIST): experience on 25 patients. World J Surg Oncol 30: 78-89.

20. Bucher P, Egger JF, Gervaz P, Ris F, Weintraub D, et al. (2006) An audit of surgical management of gastrointestinal stromal tumors (GIST). Eur J Surg Oncol 32: 310-314.

21. Joensuu H (2008) Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 39: 1411-1419.

22. Miettinen M, Lasota J (2003) Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol 54: 3-24.

23. Patil DT, Rubin BP (2011) Gastrointestinal stromal tumor: advances in diagnosis and management. Arch Pathol Lab Med 135: 1298-1310.

24. Bülbül Doğuşuoğlu Y. Turkish GIST Working Group (2012) Gastrointestinal stromal tumors: A multicenter study of 1160 Turkish cases. Turk J Gastroenterol 23: 203-211.

25. Demir L, Ekinic N, Erten C, Kucukzeybek Y, Alacacioglu A, et al. (2013) Does immunohistochemistry provide additional prognostic data in gastrointestinal stromal tumors? Asian Pac J Cancer Prev 14: 4751-4758.

26. Cappelari A, Piccolo G, Cardi F, Cavallaro A, Lo Menzo E, et al. (2013) Giant gastrointestinal stromal tumor (GIST) of the stomach cause of high bowel obstruction: surgical management. World J Surg Oncol 11: 172.

27. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, et al. (2010) AJCC Cancer Staging Handbook. (7th edn) U.S.A.

28. Koh YX, Chok AY, Zheng HL, Tan CS, Chow PK, et al. (2013) A systematic review and meta-analysis comparing laparoscopic versus open gastric resections for gastrointestinal stromal tumors of the stomach. Ann Surg Oncol 20: 3549-3560.

29. Karakousis GC, Singer S, Zheng J, Gonen M, Coit D, et al. (2011) Laparoscopic versus open gastric resections for primary gastrointestinal stromal tumors (GISTs): a size-matched comparison. Ann Surg Oncol 18: 1599-1605.

30. Matthews BD, Walsh RM, Kercher KW, Sing RF, Pratt BL, et al. (2002) Laparoscopic versus open gastric resections. Surg Endosc 16: 803-807.

31. Pitsinis V, Khan AZ, Cranshaw I, Allum WH (2007) Single center experience of laparoscopic vs. open resection for gastrointestinal stromal tumors of the stomach. Hepatogastroenterology 54: 606-608.

32. Silberhumer GR, Hufschmid M, Wrba F, Gyoeri G, Schoppmann S, et al. (2009) Lymph Node Metastasis in Gastrointestinal Stromal Tumor (GIST): to Single Centre Experience. J Clin Case Rep 5: 672. doi:10.4172/2165-7920.1000672